Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

insuline glargine

- PMLiVE

Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration

There are more than three million people affected by IBD globally, with a need to improve current treatments

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

The deal focuses on T cell-based therapies for autoimmune disease

- PMLiVE

EMA reaffirms guidance on paracetamol use during pregnancy

The guidance follows recent US comments about a possible link to autism

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy

This follows preliminary results from the company's ongoing phase 2 trial

- PMLiVE

Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

- PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

EU flag

EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

The company is planning to submit regulatory applications for the candidate by the end of the year

- PMLiVE

Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis

The rare form of psoriasis can lead to serious complications such as sepsis and heart failure

regeneron headquarters

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links